Aurora Cannabis Inc.

ACB Healthcare Drug Manufacturers Specialty & Generic

Aurora Cannabis Inc.’s revenue for fiscal 2026 (year ended March 2026) was $232.0 million, down 5.95% from fiscal 2025. In the quarter to June 2026, revenue fell 31.2%, EPS grew 75.0%, free cash flow fell 293.6% and total debt fell 82.5%, each against the same quarter a year earlier.

3.99 0.11 −2.68%
Market cap
$265.8M
P/E
0.0×
Fwd P/E
−783×
Dividend yield
—
F-score
4/9
Altman Z
−12.34
Beneish M
−2.53
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
1.28 0.90 0.80 0.82
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(11.49) 19.22 (733.60) (53.59)
P/B ratio
0.82 0.59 0.50 0.45
EV/Sales
1.15 0.74 0.53 0.58
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(25.01) (9.25) (4.89) (3.35)
Current Ratio
3.41 3.06 5.94 5.36
Net Debt/EBITDA
4.15 (9.14) 13.80 34.68
Debt/Equity
0.17 0.17 0.04 0.03
Earnings Yield
(11.58%) (25.59%) (47.71%) (50.54%)
Free Cash Flow Yield
(3.59%) (8.89%) (13.64%) (20.98%)
Free Cash Flow per Share
(0.59) 0.15 (0.08) (0.12)
Book value per Share
7.29 7.18 6.53 6.17
Free Cash Flow
(33.37) 8.67 (4.28) (7.12)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates